<DOC>
	<DOCNO>NCT00669370</DOCNO>
	<brief_summary>To determine quality life patient gastric cancer receive combination treatment docetaxel capecitabine . Secondary endpoint time progression , overall response rate overall survival . Study treatment continue disease progression unacceptable toxicity .</brief_summary>
	<brief_title>Biweekly Docetaxel Combination With Capecitabine First-Line Treatment Patients With Advanced Gastric Cancer</brief_title>
	<detailed_description>GAST-TaxXel open , phase II , single arm , non-randomized , Finnish multicenter trial . At least 50 subject enrol . Primary endpoint : To determine quality life ( EORTC QLQ-C30 QLQ-STO22 ) patient gastric cancer receive combination treatment Taxotere Xeloda . Secondary endpoint : To evaluate time progression ( TTP ) , overall response rate ( ORR ) overall survival ( OS ) . Quality life : evaluate QOL deteriorate baseline . Quality life measure use EORTC QLQ-C30 QLQ-STO22 physical functioning score primary variable . Efficacy : time progression , overall response rate , overall survival Time progression define time elapsed inclusion first document progression death whatever reason . Overall response rate assess accord RECIST criterion . Overall survival define time elapsed inclusion death . Safety : clinical laboratory toxicity symptomatology grade accord NCI-CTC criterion . Statistical consideration : The primary variable , physical functioning score measure EORTC QLQ-C30 QLQ-STO22 instrument , analyze use pair t-test ( change baseline two treatment cycle ) . A 95 % confidence interval also calculate primary variable . Median TTP OS estimate use Kaplan-Meier method . The ORR summarize . Safety variables summarize descriptively .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Inclusion criterion : Histologically confirm advanced , inoperable gastric adenocarcinoma age ≥18 year WHO performance status ≤ 2 Stage IV Measurable ( accord RECIST criterion ) evaluable lesion No previous chemotherapy , except adjuvant chemotherapy ≥ 6 month ago Adequate hematological function ( neutrophils ≥ 1.5 x 109/l platelet ≥ 100 x 109/l , Hb ≥ 100 g/l ( transfusion need ) Adequate renal function ( serum creatinine ≤ 1.25 x upper normal limit ) Adequate liver function ( total serum bilirubin ≤ 1.25 x upper normal limit ALAT ≤ 3 x upper normal limit ; case liver metastasis : total serum bilirubin ≤ 1.5 x upper normal limit , ALAT ≤ 5 x upper normal limit ) AFOS ≤ 2.5 x upper normal limit ( unless bone metastasis ) Consent form sign dated inclusion Able comply schedule followup management toxicity . Pregnant lactate woman ( potentially fertile woman use adequate contraception ) Presence CNS metastases Unresolved bowel obstruction subobstruction Chronic diarrhea Clinically significant malabsorption syndrome Inability swallow tablet Known dihydropyrimidine dehydrogenase ( DPD ) deficiency Concurrent severe and/or uncontrolled comorbid medical condition uncontrolled infection , hypertension , ischemic heart disease , myocardial infarction within previous 6 month , congestive heart failure History previous concurrent malignancy within previous 5 year except curatively treat carcinoma situ uterine cervix basal cell carcinoma skin History prior serious allergic reaction anaphylactic shock . Peripheral neuropathy ≥ grade 2 , unless related mechanical etiology Concurrent use corticosteroid unless chronic treatment ( i.e . initiate &gt; 6 month prior study entry ) low dos ( ≥ 20 mg methylprednisolone equivalent ) History allergy drug contain excipient TWEEN 80® and/ 5 fluorouracil . Lack physical integrity upper gastrointestinal tract . Concomitant administration experimental drug investigation : concurrent treatment anticancer therapy . Major surgery within 4 week prior study treatment start , lack complete recovery effect major surgery . Patients regularly follow psychological , social , family geographic reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>advanced gastric cancer</keyword>
	<keyword>adenocarcinoma</keyword>
</DOC>